Patents by Inventor Ryan Hudson

Ryan Hudson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE
    Publication number: 20190106423
    Abstract: Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.
    Type: Application
    Filed: March 10, 2017
    Publication date: April 11, 2019
    Inventors: Ryan HUDSON, Anne-Marie BEAUSOLEIL, Richard A. MILLER, Erik VERNER
  • GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
    Publication number: 20180339990
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 29, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO, RYAN HUDSON, PATRICK J. BRASSIL
  • Pyrimidine compounds as JAK kinase inhibitors
    Patent number: 10028960
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: July 24, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto
  • Neprilysin inhibitors
    Patent number: 9873696
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: January 23, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Cameron Smith, Ryan Hudson, Adam D. Hughes
  • PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20170312280
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: April 27, 2017
    Publication date: November 2, 2017
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto, Xiaojun Huang
  • Substituted naphthyridines as JAK kinase inhibitors
    Patent number: 9725470
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory bowel diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 8, 2017
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Paul R. Fatheree, Dante D. Podesto, Gary E. L. Brandt, Melissa Fleury, Anne-Marie Beausoleil
  • NEPRILYSIN INHIBITORS
    Publication number: 20170217959
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: December 14, 2016
    Publication date: August 3, 2017
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Cameron Smith, Ryan Hudson, Adam D. Hughes
  • Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease
    Publication number: 20170145044
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 25, 2017
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo
  • Neprilysin inhibitors
    Patent number: 9555041
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: January 31, 2017
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Cameron Smith, Melissa Fleury, Roland Gendron, Ryan Hudson, Adam D. Hughes
  • NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20160347772
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory bowel diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 1, 2016
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Paul R. Fatheree, Dante D. Podesto, Gary E.L. Brandt, Melissa Fleury, Anne-Marie Beausoleil, Xiaojun Huang, Venkat R. Thalladi
  • NEPRILYSIN INHIBITORS
    Publication number: 20160184316
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: July 21, 2015
    Publication date: June 30, 2016
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Cameron Smith, Melissa Fleury, Roland Gendron, Ryan Hudson, Adam D. Hughes
  • Dual-acting benzoimidazole antihypertensive agents
    Patent number: 9198899
    Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: December 1, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul Allegretti, Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • Dual-acting oxazole antihypertensive agents
    Patent number: 9181206
    Abstract: In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: November 10, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Ryan Hudson, Robert Murray McKinnell
  • Neprilysin inhibitors
    Patent number: 9120758
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: September 1, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Cameron Smith, Melissa Fleury, Roland Gendron, Ryan Hudson, Adam D. Hughes
  • Dual-acting pyrazole antihypertensive agents
    Patent number: 8822522
    Abstract: In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: September 2, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Brooke Blair, Paul R. Fatheree, Melissa Fleury, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Michael Wilson
  • DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS
    Publication number: 20140194426
    Abstract: In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: October 24, 2013
    Publication date: July 10, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Paul R. Fatheree, Ryan Hudson, Robert Murray McKinnell
  • Dual-acting antihypertensive agents
    Patent number: 8735625
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 27, 2014
    Assignee: Theravance, Inc.
    Inventors: Seok-ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar
  • DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS
    Publication number: 20140107120
    Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Paul Allegretti, Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    Publication number: 20140046075
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Application
    Filed: January 31, 2013
    Publication date: February 13, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Seok-ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar
  • Dual-acting benzoimidazole antihypertensive agents
    Patent number: 8637676
    Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: January 28, 2014
    Assignee: Theravance, Inc.
    Inventors: Paul Allegretti, Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson